August 2026 · 6 min read
BVDV — bovine viral diarrhea virus — is the most significant viral contaminant risk in fetal bovine serum. It is also one of the most misunderstood aspects of FBS quality documentation. Many researchers assume that a “BVDV negative” result on the CoA means the serum is definitively free of BVDV. It may not.
Here is what the standard test actually detects, where the limitations are, and when you need additional testing.
Why BVDV matters in FBS
BVDV is a pestivirus endemic in cattle populations globally. Persistently infected (PI) animals — calves infected in utero during the first trimester before immune competence — shed high titres of BVDV throughout their lives without clinical signs. If a PI cow contributes to a serum collection batch, the resulting FBS can contain infectious BVDV at levels that infect cell cultures without visible cytopathic effect (CPE) — meaning contamination goes undetected by routine microscopy.
BVDV contamination in cell culture causes: altered gene expression, interferon pathway activation, subtle growth changes that confound experimental data, and — critically — viral transmission to biopharmaceutical products manufactured in those cells. A 2025 Frontiers in Veterinary Science study identified infectious BVDV in commercial FBS that was confirmed by both indirect immunofluorescence and electron microscopy following six serial passages in MDBK cells. This illustrates that BVDV in commercial FBS remains an active real-world risk, not a theoretical one.
Standard CoA BVDV testing — what it covers
The standard BVDV test on most FBS CoAs is the cytopathic effect (CPE) assay — also called the virus isolation assay. In this test:
- FBS is inoculated onto MDBK (Madin-Darby bovine kidney) cells, which are susceptible to BVDV
- Cultures are observed over 7–14 days for visible cytopathic effect
- A positive result = visible cell destruction or morphology change
- A negative result = no visible CPE detected
The limitation: the CPE assay only detects cytopathic BVDV strains. BVDV exists in two biotypes — cytopathic (cp) and non-cytopathic (ncp). The non-cytopathic biotype produces no CPE in cell culture despite active replication. PI cattle are persistently infected with ncp-BVDV — the most common source of FBS contamination — and ncp-BVDV will give a false negative CPE result.
Standard FBS CoA BVDV testing also includes antibody detection (ELISA or neutralisation assay) to detect anti-BVDV antibodies from immune animals in the donor pool. This is an indirect measure of viral exposure but does not directly detect viral RNA or infectious particles.
BVDV RNA/qPCR testing — what it adds
RT-qPCR (reverse transcription quantitative PCR) targeting conserved regions of the BVDV genome detects both cytopathic and non-cytopathic BVDV strains directly, without relying on cell culture. It is:
- More sensitive: detects as few as 10–100 viral genome copies per mL
- Faster: results in 24–48 hours vs 7–14 days for CPE assay
- Biotype-independent: detects ncp-BVDV that the CPE assay misses
- Strain-inclusive: can be designed to detect BVDV-1, BVDV-2, and BVDV-3 (emerging strains)
BVDV RNA/qPCR is not standard on SeamlessBio FBS CoAs. It is an additional, separately documented service available on request — for applications where comprehensive viral safety documentation is required.
When do you need BVDV RNA/qPCR?
| Application | Standard CPE sufficient? | BVDV RNA/qPCR recommended? |
|---|---|---|
| General research cell culture | Yes — adequate for routine work | Not required |
| Vaccine production (Vero, BHK, MDCK) | No — ncp-BVDV contamination undetectable by CPE | Yes — regulatory expectation |
| ATMP / clinical-grade cell manufacturing | No — EMA and FDA expect comprehensive viral safety | Yes — required for GMP submissions |
| AAV / viral vector production (clinical) | No | Yes — IND/BLA raw material documentation |
| Hybridoma / mAb production (research) | Yes — adequate | Optional — consider if data will support regulatory submission |
| ES cell / iPSC banking | Borderline — depends on downstream use | Recommended for cells intended for clinical use |
What SeamlessBio’s standard CoA covers
Every SeamlessBio FBS lot ships with a CoA documenting:
- Sterility (USP <71>)
- Mycoplasma (PCR)
- Endotoxin (LAL chromogenic)
- Haemoglobin, total protein, albumin, globulin
- IgG concentration
- Cell culture performance test (MRC-5, L-929, HeLa)
- Viral panel by CPE: BRSV, BVDV, BHV-1, PI-3
- Antibody testing: BVDV-1, BVDV-2, BVDV-3, BHV-1, PI-3
BVDV RNA/qPCR is not included in the standard CoA. If your application requires it, contact us to arrange additional testing on your specific lot — we provide this as a separately documented service with full test records included in the lot documentation package.
Gamma irradiation as an alternative to RNA testing
For applications where the primary concern is viral inactivation rather than detection, gamma irradiation (25–45 kGy) of FBS provides a validated inactivation step for BVDV and most other relevant bovine viruses. Gamma irradiation is accepted by EMA and FDA as a viral reduction step in the raw material risk assessment for GMP manufacturing. It does not eliminate the need for BVDV RNA testing in all regulatory contexts but can reduce the overall risk profile significantly.
SeamlessBio offers Gamma Irradiated FBS with irradiation certificate and dose mapping as standard documentation.
Further reading:
- FBS Lot Testing Protocol — Step-by-Step Guide
- FBS Portfolio — All Grades
- AAV Viral Vector Production — FBS Guide
Need BVDV RNA/qPCR testing? info@seamlessbio.de | Request documentation
English 
Deutsch